Last reviewed · How we verify
DHA-PQP and PQ starting on Day 42
DHA-PQP and PQ starting on Day 42 is a Antimalarial combination therapy Small molecule drug developed by Fundação de Medicina Tropical Dr. Heitor Vieira Dourado. It is currently in Phase 3 development for Plasmodium vivax malaria treatment and relapse prevention, Plasmodium falciparum malaria treatment. Also known as: Experimental treatment with no potential synergy.
DHA-PQP and PQ are antimalarial combination drugs that work by disrupting parasite metabolism and preventing malaria transmission.
DHA-PQP and PQ are antimalarial combination drugs that work by disrupting parasite metabolism and preventing malaria transmission. Used for Plasmodium vivax malaria treatment and relapse prevention, Plasmodium falciparum malaria treatment.
At a glance
| Generic name | DHA-PQP and PQ starting on Day 42 |
|---|---|
| Also known as | Experimental treatment with no potential synergy |
| Sponsor | Fundação de Medicina Tropical Dr. Heitor Vieira Dourado |
| Drug class | Antimalarial combination therapy |
| Target | Plasmodium falciparum and Plasmodium vivax parasites; heme detoxification pathway; mitochondrial function |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Dihydroartemisinin-piperaquine (DHA-PQP) combines a fast-acting artemisinin derivative with a longer-acting quinoline to eliminate blood-stage parasites, while primaquine (PQ) targets hypnozoites in the liver to prevent relapse in P. vivax and P. ovale malaria. This combination provides both rapid parasite clearance and prevention of recurrent infections.
Approved indications
- Plasmodium vivax malaria treatment and relapse prevention
- Plasmodium falciparum malaria treatment
Common side effects
- Nausea
- Vomiting
- Abdominal pain
- Headache
- Hemolysis (with primaquine in G6PD deficiency)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DHA-PQP and PQ starting on Day 42 CI brief — competitive landscape report
- DHA-PQP and PQ starting on Day 42 updates RSS · CI watch RSS
- Fundação de Medicina Tropical Dr. Heitor Vieira Dourado portfolio CI
Frequently asked questions about DHA-PQP and PQ starting on Day 42
What is DHA-PQP and PQ starting on Day 42?
How does DHA-PQP and PQ starting on Day 42 work?
What is DHA-PQP and PQ starting on Day 42 used for?
Who makes DHA-PQP and PQ starting on Day 42?
Is DHA-PQP and PQ starting on Day 42 also known as anything else?
What drug class is DHA-PQP and PQ starting on Day 42 in?
What development phase is DHA-PQP and PQ starting on Day 42 in?
What are the side effects of DHA-PQP and PQ starting on Day 42?
What does DHA-PQP and PQ starting on Day 42 target?
Related
- Drug class: All Antimalarial combination therapy drugs
- Target: All drugs targeting Plasmodium falciparum and Plasmodium vivax parasites; heme detoxification pathway; mitochondrial function
- Manufacturer: Fundação de Medicina Tropical Dr. Heitor Vieira Dourado — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Plasmodium vivax malaria treatment and relapse prevention
- Indication: Drugs for Plasmodium falciparum malaria treatment
- Also known as: Experimental treatment with no potential synergy
- Compare: DHA-PQP and PQ starting on Day 42 vs similar drugs
- Pricing: DHA-PQP and PQ starting on Day 42 cost, discount & access